<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04257617</url>
  </required_header>
  <id_info>
    <org_study_id>ZL-1201-001</org_study_id>
    <nct_id>NCT04257617</nct_id>
  </id_info>
  <brief_title>A Trial of ZL-1201 in Subjects With Advanced Cancer</brief_title>
  <official_title>First in Human, Phase I Trial of ZL-1201 in Subjects With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zai Lab (Shanghai) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zai Lab (Hong Kong), Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in Human, Phase I Trial of ZL-1201 in Subjects with Advanced Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, dose escalation trial of ZL-1201. The major aims of the study are&#xD;
      to define the safety profile of this new drug, and to determine a recommended dose and&#xD;
      schedule for potential additional trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ZL-1201 when administered as an intravenous (IV) infusion: Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>From the time of informed consent to 30 days after last dose</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics：AUC</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
    <description>The area under the curve (AUC) of serum concentration of the drug after the administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
    <description>Maximum serum concentration(Cmax) of the drug after the administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: t1/2</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
    <description>Half-life(t1/2) of the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: CL</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
    <description>Total body clearance of the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Vss</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
    <description>Volume of the distrubution at steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
    <description>Anti-Drug Antibodies (ADA) will be tested and percentage of ADA positive patients will be calculated to evaluate immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR）</measure>
    <time_frame>Up to 2 years after enrollment</time_frame>
    <description>ORR includes CR and PR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Single arm, ZL-1201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm, ZL-1201</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZL-1201</intervention_name>
    <description>Part 1 &amp; 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2.</description>
    <arm_group_label>Single arm, ZL-1201</arm_group_label>
    <other_name>Monotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically/cytologically confirmed, locally advanced unresectable or metastatic&#xD;
             solid tumors and lymphomas that are refractory or intolerant to standard of care&#xD;
             therapy, or for which no standard therapy exists.&#xD;
&#xD;
          -  Adequate hematologic status&#xD;
&#xD;
          -  Adequate coagulation function&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known active brain metastases&#xD;
&#xD;
          -  Red blood cells transfusion dependence&#xD;
&#xD;
          -  Known cardiopulmonary disease&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
          -  Any other serious underlying medical&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>Zai Laboratory</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Physician</last_name>
    <phone>+86 21 6163 2588</phone>
    <email>ZL-1201-001@zailaboratory.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>US2004</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>US2005</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>US2001</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>US2003</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>US2002</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11776</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CN1003</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CN1002</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumors or hematologic malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

